CN1652821A - 抗前列腺特异性膜抗原(psma)的人单克隆抗体 - Google Patents

抗前列腺特异性膜抗原(psma)的人单克隆抗体 Download PDF

Info

Publication number
CN1652821A
CN1652821A CNA038073714A CN03807371A CN1652821A CN 1652821 A CN1652821 A CN 1652821A CN A038073714 A CNA038073714 A CN A038073714A CN 03807371 A CN03807371 A CN 03807371A CN 1652821 A CN1652821 A CN 1652821A
Authority
CN
China
Prior art keywords
antibody
human
psma
cell
people
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038073714A
Other languages
English (en)
Chinese (zh)
Inventor
Y·M·德奥
R·格拉奇尔诺
D·哈森
E·H·霍尔梅斯
W·T·蒂诺
A·布拉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of CN1652821A publication Critical patent/CN1652821A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA038073714A 2002-01-28 2003-01-28 抗前列腺特异性膜抗原(psma)的人单克隆抗体 Pending CN1652821A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5998902A 2002-01-28 2002-01-28
US10/059,989 2002-01-28

Publications (1)

Publication Number Publication Date
CN1652821A true CN1652821A (zh) 2005-08-10

Family

ID=27658271

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038073714A Pending CN1652821A (zh) 2002-01-28 2003-01-28 抗前列腺特异性膜抗原(psma)的人单克隆抗体

Country Status (10)

Country Link
EP (1) EP1519747A4 (enExample)
JP (1) JP2005518789A (enExample)
KR (1) KR20040077889A (enExample)
CN (1) CN1652821A (enExample)
AU (1) AU2003224604B2 (enExample)
BR (1) BR0307216A (enExample)
CA (1) CA2474616A1 (enExample)
MX (1) MXPA04007262A (enExample)
NZ (1) NZ534687A (enExample)
WO (1) WO2003064606A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171248A (zh) * 2008-10-01 2011-08-31 米克罗麦特股份公司 种间特异性PSMAxCD3双特异性单链抗体
CN101891818B (zh) * 2009-01-16 2012-07-25 中国人民解放军第四军医大学 抗人前列腺特异性膜抗原胞外区单链抗体及其应用
CN103333249A (zh) * 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
CN101443340B (zh) * 2006-03-14 2013-12-04 癌靶技术有限责任公司 前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法
CN108025063A (zh) * 2015-03-10 2018-05-11 索伦托治疗有限公司 结合psma的抗体治疗剂
WO2021164692A1 (zh) * 2020-02-18 2021-08-26 和铂医药(上海)有限责任公司 一种分离的结合抗原psma的蛋白及其用途

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
US20050191293A1 (en) * 2003-12-10 2005-09-01 Shrikant Deshpande IP-10 antibodies and their uses
JP4588763B2 (ja) * 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
PL1735348T3 (pl) * 2004-03-19 2012-11-30 Imclone Llc Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
CN1997670B (zh) 2004-07-01 2014-04-30 诺和诺德公司 人类抗-kir抗体
PL1836225T3 (pl) 2005-01-06 2012-05-31 Novo Nordisk As Czynniki wiążące kir i sposoby ich stosowania
JP5249587B2 (ja) * 2005-02-18 2013-07-31 メダレックス， インク． フコシル残基を欠く前立腺特異的膜抗原（ｐｓｍａ）に対するモノクローナル抗体
DK1851250T3 (da) * 2005-02-18 2012-07-09 Medarex Inc Humant monoklonalt antistof mod prostataspecifikt membranantigen (psma)
EP2418278A3 (en) * 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
PT2326350E (pt) 2008-09-08 2013-12-10 Psma Dev Company L L C Compostos para matar células cancerosas resistentes a taxano, que expressam psma
WO2010118522A1 (en) * 2009-04-14 2010-10-21 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR20190080992A (ko) 2015-05-21 2019-07-08 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
KR101704379B1 (ko) * 2015-10-27 2017-02-08 (주)알테오젠 항체-약물 접합체 및 그 제조방법
CN109071637B (zh) 2016-03-23 2022-03-22 首尔大学校产学协力团 结合严重发热伴血小板减少综合征病毒的包膜糖蛋白的抗体及其用途
PL3461261T3 (pl) 2016-05-20 2025-11-12 Harpoon Therapeutics, Inc. Białka wiążące jednołańcuchowy fragment zmienny CD3
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
KR20210087108A (ko) 2016-11-23 2021-07-09 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
MX2019006045A (es) * 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Proteinas triespecificas dirigidas a psma y metodos de uso.
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
PL3694529T3 (pl) 2017-10-13 2024-12-16 Harpoon Therapeutics, Inc. Trójswoiste białka i sposoby zastosowania
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
KR20220144841A (ko) 2020-02-21 2022-10-27 하푼 테라퓨틱스, 인크. Flt3 결합 단백질 및 사용 방법
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023088966A1 (en) 2021-11-19 2023-05-25 Adc Therapeutics Sa Anti-psma conjugates
WO2024118940A1 (en) * 2022-12-01 2024-06-06 Twist Bioscience Corporation Anti-psma antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2155854T3 (es) * 1993-06-09 2001-06-01 Unilever Nv Procedimiento de produccion de proteinas de fusion que comprende fragmentos de scfv con la ayuda de un molde transformado.
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
ES2277846T3 (es) * 1999-07-29 2007-08-01 Medarex, Inc. Anticuerpos monoclonales humanos para antigeno prostatico especifico.
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
MXPA02012434A (es) * 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
EP2360169B1 (en) * 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
DK1539221T3 (da) * 2002-08-30 2010-05-03 Biorexis Pharmaceutical Corp Transferrin-fusionsproteinbiblioteker
US20050058649A1 (en) * 2002-12-02 2005-03-17 Landes Gregory M. Antibodies directed to phospholipase A2 and uses thereof

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101443340B (zh) * 2006-03-14 2013-12-04 癌靶技术有限责任公司 前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法
CN102171248A (zh) * 2008-10-01 2011-08-31 米克罗麦特股份公司 种间特异性PSMAxCD3双特异性单链抗体
CN102171248B (zh) * 2008-10-01 2015-07-15 安进研发（慕尼黑）股份有限公司 种间特异性PSMAxCD3双特异性单链抗体
CN101891818B (zh) * 2009-01-16 2012-07-25 中国人民解放军第四军医大学 抗人前列腺特异性膜抗原胞外区单链抗体及其应用
CN103333249A (zh) * 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
WO2014198223A1 (zh) * 2013-06-14 2014-12-18 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原(psma)的单克隆抗体及其应用
CN108025063A (zh) * 2015-03-10 2018-05-11 索伦托治疗有限公司 结合psma的抗体治疗剂
WO2021164692A1 (zh) * 2020-02-18 2021-08-26 和铂医药(上海)有限责任公司 一种分离的结合抗原psma的蛋白及其用途

Also Published As

Publication number Publication date
EP1519747A2 (en) 2005-04-06
AU2003224604B2 (en) 2007-06-14
BR0307216A (pt) 2005-12-20
WO2003064606A2 (en) 2003-08-07
EP1519747A4 (en) 2006-03-29
KR20040077889A (ko) 2004-09-07
CA2474616A1 (en) 2003-08-07
JP2005518789A (ja) 2005-06-30
WO2003064606A3 (en) 2005-02-03
MXPA04007262A (es) 2004-10-29
NZ534687A (en) 2007-10-26

Similar Documents

Publication Publication Date Title
CN1652821A (zh) 抗前列腺特异性膜抗原(psma)的人单克隆抗体
CN1500097A (zh) 抗Fcα受体(CD89)的人单克隆抗体
CN1638800A (zh) 抗cd30的人类单克隆抗体
CN1966525A (zh) 表皮生长因子受体(egfr)的人单克隆抗体
CN100400547C (zh) 前列腺特异膜抗原的人类单克隆抗体
US9458236B2 (en) Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CN1729203A (zh) 抗cd20的人单克隆抗体
CN1889979A (zh) Ip－10抗体及其用途
AU2003224604A1 (en) Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
AU2002240338A1 (en) Human monoclonal antibodies to FC alpha receptor (CD89)
CN1452636A (zh) 抗树突细胞的人单克隆抗体
CN1399645A (zh) Her2/neu的人单克隆抗体
CN1745101A (zh) 针对肿瘤坏死因子的抗体及其用途
CN1571836A (zh) 白介素15(il－15)特异性人抗体
CN1950107A (zh) Irta－5抗体及其用途
CN1889978A (zh) 干扰素α抗体及其用途
CN101056655A (zh) 治疗cd30阳性淋巴瘤的方法
CN1780856A (zh) 白介素15(il－15)的特异性人抗体
CN1809591A (zh) 针对炭疽芽孢杆菌保护性抗原的人单克隆抗体
CN101044165A (zh) Irta－4抗体及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication